Clinical trials: Rectal Neoplasms
Metastatic Colorectal Cancer (mCRC)
Evaluation of a Diagnostic Test to Identify the Best Drugs for Treatment of Metastatic Colorectal Cancer
DSEE-CRC is a top-tier Norwegian and Swedish public-private partnership for the development of µCAN, a unique patient-centric, therapy-guiding in vitro diagnostic test to improve cancer treatment outcomes for metastatic…
- Trial name
- DSEE-CRC (NCT07171554)
- Testing
- µCAN drug screen test, Standard-of-Care Therapy
- Where
- Norway
- Volunteers
- 75 people
- Sponsor
- Oncosyne AS
Colorectal Cancer
Comparison of Fecal Ribonucleic Acid (RNA) Test With Fecal Occult Blood Test (FOBT) for Detecting Colorectal Cancer and Adenoma
Colorectal cancer (CRC) is the second common cause of death in the Western world, and is very increasing in Japan. Fecal occult blood test (FOBT) is used routinely for CRC screening, which has been shown to reduce the incidence…
- Trial name
- NCT00197405
- Where
- Japan
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Hamamatsu University
Colorectal Neoplasms
Clinical Study of Apatinib Combined With Second - Line Chemotherapy for Metastatic Colorectal Cancer
(1) Evaluate the efficacy of apatinib in combination with standard second-line chemotherapy for advanced colorectal cancer. Whether it can prolong Progression Free Survival (PFS), overall survival (OS) in patients with advanced…
- Trial name
- NCT03412994
- Testing
- Apatinib, standard second-line chemotherapy
- Volunteers
- 60 people
- Sponsor
- Liqiang Zhong
Cervical Cancer
Hydrogel Spacer During Definitive Radiotherapy for Cervical Cancer
This prospective, single-center study will evaluate the feasibility, spatial stability, and dosimetric effects of an absorbable hydrogel spacer placed between the cervix/vagina and rectum before definitive radiotherapy for…
- Trial name
- Hydrogel-RT (NCT07904182)
- Testing
- Absorbable Hydrogel Spacer
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Colorectal Cancer, Early Onset Colorectal Cancer
Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer
An increase in early-onset colorectal cancers (eoCRC), defined as a CRC before 50 years, is confirmed globally. CRC pathogenesis has been associated with several risk factors (family history, germline pathogenic variants…
- Conditions
- Colorectal Cancer, Early Onset Colorectal Cancer, Diet Habit, Risk Reduction
- Trial name
- DEMETRA (NCT05732623)
- Testing
- Semi Quantitative Food Frequency Questionnaire (SQFFQ)
- Where
- 8 sites in United States, Finland and 4 more
- Volunteers
- 2,300 people, healthy volunteers welcome
- Sponsor
- San Raffaele University
Rectal Cancer
Rectal Cancer Neoadjuvant Therapy-Real World Study
This study aims to utilise a real-world data platform to integrate multi-omics data-including radiomics, gut microbiota, pathological quality control and liquid biopsy-to construct a multidimensional predictive model for the…
- Trial name
- RC-NAT-RWS (NCT07566559)
- Testing
- This study is a multicenter, real-world, non-interventional study.
- Where
- China
- Volunteers
- 869 people
- Sponsor
- Beijing Friendship Hospital
Rectal Cancer, Organ-Space Surgical Site Infection
Concordance Between Monitoring Systems for Organ/Space Surgical Site Infections in Rectal Surgery
The Catalan Cancer Plan (CCP) undertakes periodic audits of cancer treatment outcomes, including organ/space surgical site infections (O/S-SSI) rates, while the Catalan Healthcare-associated Infections Surveillance Programme…
- Trial name
- NCT06104579
- Testing
- Person-level linkage of both databases looking for concordance in the diagnosis of organ-space surgical site infection
- Where
- Spain
- Volunteers
- 11,367 people
- Sponsor
- Hospital de Granollers
Locally Advanced Rectal Cancer (LARC)
Total Neoadjuvant Treatment With or Without Tislelizumab for Locally Advanced Rectal Cancer.
This prospective, multi-center, phase II randomized controlled trial will evaluate the actual benefit of adding immunotherapy with tislelizumab to the currently most effective approach against LARC, namely TNT.
- Trial name
- TOTAL (NCT06940388)
- Testing
- Tislelizumab, Total neoadjuvant therapy (TNT)
- Where
- 2 sites in Germany, Israel
- Volunteers
- 134 people
- Sponsor
- brenner baruch
Pancreatic Cyst, Pancreatitis, Acute
Rectal Indomethacin to Prevent Acute Pancreatitis in EUS-FNA of Pancreatic Cysts
The aim of this randomized trial is to compare the rate of post-procedure pancreatitis in patients undergoing EUS-FNA of pancreatic cysts; patients will receive either a single dose of indomethacin or placebo administered…
- Trial name
- NCT05572788
- Testing
- EUS-guided fine needle aspiration of pancreatic cysts
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Orlando Health, Inc.
Solid Tumor, Adult, Lung Adenocarcinoma
TP53 R248Q TCR-T Cell Therapy for Advanced Solid Tumor
To evaluate the safety and efficacy of T cell therapy with mutated TP53 R248Q specific TCR transduction in patients with advanced solid tumor expressing the TP53 R248Q mutation and the HLA-A*11:01 allele.
- Conditions
- Solid Tumor, Adult, Lung Adenocarcinoma, Pancreas Cancer, Colorectal Cancer
- Trial name
- NCT06619886
- Testing
- Autologous, engineered T Cells targeting TP53 R248Q
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Colorectal Cancer
An Observational Study of Xeloda (Capecitabine) Monotherapy in Patients With Colorectal Cancer (AXEL)
This observational study will evaluate Xeloda (capecitabine) monotherapy on the effect of disease-free survival in patients with colon cancer stage III (Duke C) after surgical resection. Data will be collected for 3 years.
- Trial name
- NCT01276405
- Where
- Romania
- Volunteers
- 123 people
- Sponsor
- Hoffmann-La Roche
Rectal Cancer
Phase II Trial to Evaluate Laparoscopic Surgery for Stage 0/I Rectal Carcinoma
The purpose of this study is to examine the technical and oncological feasibility of laparoscopic surgery for rectal carcinoma
- Trial name
- Lap RC (NCT00635466)
- Testing
- laparoscopic surgery for rectal carcinoma
- Where
- Japan
- Volunteers
- 495 people
- Sponsor
- Japan Society of Laparoscopic Colorectal Surgery
Colorectal Neoplasms
Aflibercept +/- LV5FU2 in First Line of Non-resectalbe Metastatic Colorectal Cancers
This is what the FFCD 11-01 - PRODIGE 25 trial proposes to study, as a preliminary for strategic studies evaluating the usefulness of including targeted therapeutics from the first line with aflibercept +/- LV5FU2.
- Trial name
- FOLFA (NCT02384759)
- Testing
- aflibercept, LV5FU2
- Where
- 58 sites in France
- Volunteers
- 117 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Colorectal Cancer
A Comparative Study Between Early Onset Colorectal Cancer and Late Onset Colorectal Cancer Patients
This study aims to investigate the clinical, socioeconomic, behavioral, genetic, and molecular factors characterizing Early Onset Colorectal Cancer (EOCRC) patients compared with Late Onset Colorectal Cancer (LOCRC) patients
- Trial name
- EOrOS (NCT06326879)
- Testing
- No intervention
- Where
- Italy
- Volunteers
- 340 people
- Sponsor
- Istituto Clinico Humanitas
Metastatic Colorectal Cancer
Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC
This is an exploratory, non-controlled, multi-cohort, phase II small-sample clinical study designed to evaluate the clinical benefit of second-line treatment with anlotinib plus irinotecan or further in combination with a PD-1…
- Trial name
- NCT05229003
- Testing
- Anlotinib, Penpulimab, Irinotecan
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Fudan University
Metastatic Colorectal Cancer
Simvastatin + Cetuximab/Irinotecan in K-ras Mutant Colorectal Cancer (CRC)
Based on the results from preclinical study, the investigators suggest that the addition of simvastatin at a dose of cardiovascular use (40 ~ 80 mg qd daily) may overcome cetuximab resistance in KRAS mutant colorectal cancer via…
- Trial name
- NCT01281761
- Testing
- cetuximab/irinotecan/simvastatin
- Where
- South Korea
- Volunteers
- 52 people
- Sponsor
- Samsung Medical Center
Metastatic Colorectal Cancer
Oxaliplatin, 5-FU and Leucovorin in Combination With Oral Capecitabine for Metastatic Colorectal Cancer
The combination of oxaliplatin, 5-FU, leucovorin, and capecitabine is hypothesized to retain and potentially improve upon the activity of the FOLFOX regimens.
- Trial name
- NCT00205322
- Testing
- chemotherapy (capecitabine, oxaliplatin, 5-FU, leucovorin)
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Wisconsin, Madison
Colorectal Cancer
Colonoscopic Skill Acquisition and Transfer Via Simulated Curriculum of Progressive Training
It is hypothesized that a progressive simulated learning strategy will result in better global clinical performance (e.g., technical, communication) and transfer of endoscopic skill, as compared with a high-fidelity simulation…
- Trial name
- NCT02000180
- Testing
- Progressive Group
- Where
- Canada
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Unity Health Toronto
Colorectal Neoplasms
The Safety and Tolerability of PD-L1 Monoclonal Antibody Plus Lenalidomide in The Treatment of Colorectal Cancer
This study proposed by increasing dosage and expand the "3 + 3" queue, main component is divided into two phases, phase 1 for dose escalation, according to preliminary data recommended doses starting dose of climbing, the purpose…
- Trial name
- NCT04326296
- Testing
- PD-L1 Monoclonal Antibody Combined With Lenalidomide
- Where
- China
- Volunteers
- 33 people
- Sponsor
- LiNing
Rectal Cancer
Timisnar - Biomarkers Substudy (Timisnar-mirna)
Neoadjuvant chemoradiotherapy (nCHT) followed by surgery is the mainstay treatment for locally advanced rectal cancer, leading to significant decrease in tumor size (downsizing) and a shift towards earlier disease stage in the…
- Trial name
- TiMiSNAR-miRNA (NCT03962088)
- Testing
- miRNA
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria